These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 35320942)

  • 1. Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.
    Guo R; Lu W; Zhang Y; Cao X; Jin X; Zhao M
    Front Immunol; 2022; 13():839097. PubMed ID: 35320942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 5. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
    Martino M; Paviglianiti A
    Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948
    [No Abstract]   [Full Text] [Related]  

  • 6. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
    Wu JF; Dhakal B
    J Hematol Oncol; 2023 Jul; 16(1):86. PubMed ID: 37507805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCMA-targeted immunotherapy for multiple myeloma.
    Yu B; Jiang T; Liu D
    J Hematol Oncol; 2020 Sep; 13(1):125. PubMed ID: 32943087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
    Xia J; Li Z; Xu K
    J Hematol Oncol; 2023 Jun; 16(1):60. PubMed ID: 37277826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BCMA in Multiple Myeloma.
    Tan CR; Shah UA
    Curr Hematol Malig Rep; 2021 Oct; 16(5):367-383. PubMed ID: 34432234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
    Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
    J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
    Yang J; Zhou W; Li D; Niu T; Wang W
    Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
    Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
    Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I; Bago JR; Hajek R; Jelinek T
    Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOHO State-of-the-Art Updates and Next Questions | BCMA-Directed CAR T-Cells: Early Results and Future Directions.
    Biltibo E; Berdeja JG
    Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):310-321. PubMed ID: 36925390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them.
    Rees MJ; Kumar S
    Leuk Lymphoma; 2024 Mar; 65(3):287-300. PubMed ID: 38354090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events.
    Watson E; Djebbari F; Rampotas A; Ramasamy K
    Expert Rev Hematol; 2022 Jun; 15(6):503-517. PubMed ID: 35633050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rethinking mechanisms of neurotoxicity with BCMA directed therapy.
    Mohyuddin GR; Banerjee R; Alam Z; Berger KE; Chakraborty R
    Crit Rev Oncol Hematol; 2021 Oct; 166():103453. PubMed ID: 34461271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.